Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
M3 ( (JP:2413) ) has shared an update.
M3, Inc. has approved a share repurchase program of up to 20 million common shares, representing about 3.00% of outstanding stock, for a total consideration of up to 20 billion yen. The buyback, to be executed via open-market purchases on the Tokyo Stock Exchange between May 2, 2026 and April 30, 2027, accompanies a dividend as part of an expanded shareholder return policy for the current fiscal year.
The company frames the repurchase as a result of a comprehensive review of capital allocation in light of its financial position, earnings outlook, stock valuation and the Tokyo Stock Exchange’s call for cost-of-capital-focused management. By combining internal reinvestment for new business development with flexible buybacks, M3 aims to sustain growth, improve capital profitability metrics such as ROE, and reinforce its market standing amid volatile tech valuations and geopolitical uncertainty.
The most recent analyst rating on (JP:2413) stock is a Hold with a Yen2050.00 price target. To see the full list of analyst forecasts on M3 stock, see the JP:2413 Stock Forecast page.
More about M3
M3, Inc., listed on the TSE Prime Market, operates in the digital healthcare and medical information services industry, providing online platforms and technology solutions for medical professionals. Headquartered in Tokyo, the company focuses on expanding technology-driven healthcare businesses in Japan and globally, while emphasizing capital efficiency and shareholder value.
Average Trading Volume: 4,993,856
Technical Sentiment Signal: Sell
Current Market Cap: Yen1021.3B
For detailed information about 2413 stock, go to TipRanks’ Stock Analysis page.